IGC Pharma
IGC Pharma: A US-based biopharmaceutical firm developing cannabinoid therapies for various conditions.
IGC Pharma: A US-based biopharmaceutical firm developing cannabinoid therapies for various conditions.
Founded with a mission to develop innovative cannabinoid-based therapies, IGC Pharma, Inc. focuses on addressing significant medical conditions such as Alzheimer's disease, period cramps, premenstrual syndrome (PMS), and chronic pain. The company aims to revolutionize the healthcare sector in the United States by offering novel treatments that leverage the therapeutic potential of cannabinoids. One of their key products, IGC-AD1, is currently in Phase 2b trials for treating agitation in dementia due to Alzheimer's disease, showcasing their commitment to tackling complex neurological disorders.
IGC Pharma has garnered attention through its research and development efforts, particularly in the field of Alzheimer's disease. The company's leadership includes experienced professionals in biopharmaceuticals and cannabinoid research, contributing to its growing reputation in the industry. Notable investors and partnerships have supported its innovative approach, enabling significant advancements in clinical trials. Overall, IGC Pharma's impact lies in its potential to provide effective cannabinoid-based treatments, offering hope to millions affected by chronic and debilitating conditions.
Companies similar to IGC Pharma include IGC BIO, Icvrx, Ikaria and Pure Green Pharmaceuticals.
IGC Pharma was founded in 2005.
IGC Pharma's headquarters is located in Potomac, MD, US.
IGC Pharma's most recent funding round was for $12M (USD) in July 2023.
As of Jul 7, 2023, IGC Pharma has raised a total of $15.3M (USD).
IGC Pharma has 50 employees as of Feb 6, 2024.
